Trading at a very low 13.77 P/E ratio.
Short interest is quiet high at 9.15%, which could ignite a rally.
Bristol-Myers Squibb resumed with Buy rating and $60 (16% upside) price target at BofAML.
Company profile
Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products....
Bristol Myers looks to be headed to the long term descending trend line. For now it is in an uptrend due to reduced pressure on drug companies in the USA from prospective Democratic Presidents.
Be sure to drop a like and a follow if you found this helpful. Also check out my revamped stocktwits page @CJ3W and follow me on Twitter @CJ3W. Cheers!
We are of the opinion that the recent resistance level @ $54 looks on the near term horizon, momentum has been strong, but volume is on the decline.
Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and...
I identified rising channel developing in BMY, it seems that I might enter it too late. However, the momentum in the market for Healthcare is strong. I bought a call vertical for the trade
Entry:
Nice wedge pattern on this. Although it's been in a downtrend, it weathered the past week's volatility quite well, so my guess is sellers are exhausted here in the short-medium term.
This is a $75B global pharmaceutical company, makes a bunch of important drugs, that is trading at 12 P/E and pays 3.5% dividend.
They are acquiring Celgene (CELG), a similar...
BMY is slightly above its long-term trend line. It doesn't appear to have breakout volume right now, but the move implies investor optimism about tomorrow's earnings. Zacks has given BMY a positive earnings surprise prediction.
Bearish
-Descending Triangle
-bearish divergence
Bullish
-At historic support level
-30th September expiration date of the offers to exchange (Celgene) could see a trend reversal
Bristol-Myers Squibb upgraded to Overweight with a $55 (17% upside) price target at Barclays. Shares up 1% premarket.
Post earnings BMY has had some nice price action, investors liked what the heard from the earnings report and the analysts have started to upgrade the stock as of today. Sentiment in the Pharma sector has been horrendous for months, so maybe a...
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
BMY
![BMY: [Idea Long] BMY and CELG](https://s3.tradingview.com/c/CLP0ioIV_mid.png "[Idea Long] BMY and CELG")
